IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone

Dr Jitendra Singh commends SCTIMST doctors for treating 17,000 patients under AB-PMJAY

At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem

Glenmark Pharma introduces Vancomycin Injection in U.S. market

The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.

RAG launches lupus patient support group in Ahmedabad

The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care